David W. Denning
Nessuna posizione attualmente
Storia della carriera di David W. Denning
Precedenti posizioni note di David W. Denning
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Stanford University | Corporate Officer/Principal | 01/01/1987 | 01/01/1990 |
| The University of Manchester | Corporate Officer/Principal | 01/01/1990 | - |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Direttore/Membro del Consiglio | 01/01/1998 | - |
| Fondatore | 01/01/1998 | - | |
Myconostica Ltd.
 Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Direttore/Membro del Consiglio | 14/09/2009 | - |
| Presidente | - | 14/09/2009 | |
| Direttore Tecnico/Scientifico/R&S | 14/09/2009 | - | |
| Fondatore | 14/09/2009 | - |
Statistiche
Distribuzione geografica
| Regno Unito | 3 |
| Stati Uniti | 2 |
| Israele | 2 |
Posizioni
| Director/Board Member | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Settori
| Consumer Services | 3 |
| Electronic Technology | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Myconostica Ltd.
Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Electronic Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- David W. Denning
- Esperienza
